Research topics
Biomarker research articles covering molecular signals, prediction tools, and measures used to study Crohn's disease, ulcerative colitis, or broader IBD.
Page 6 of 8 · 360 articles
UGI involvement in children with IBD was common and linked to a more severe disease course — lower remission rates and more frequent need for biologic therapy — which could affect monitoring and treatment planning.
This review examines a noninvasive neuromodulation strategy (ta‑VNS) that might modulate immune and gut‑barrier biomarkers in IBD and could become an adjunctive therapy if validated in trials. Patients and clinicians may...
This registered Phase 2/3 program is evaluating guselkumab (an IL‑23 inhibitor) for moderate–severe Crohn's disease and could expand treatment options if trials show benefit and safety. The studies include clinical and...
Environmental exposures from agricultural chemicals may affect the gut microbiome and intestinal inflammation, which could be one factor influencing IBD risk or flares. Understanding these links could point to preventive...
Frequent, accurate assessment of bowel inflammation and fibrosis is critical for Crohn's disease care. Ultrasound is safe, accessible, and could provide a low-cost biomarker to monitor disease activity, fibrosis, and...
Combination (dual) therapy is an active area of research because many people with Crohn’s disease don’t achieve lasting remission on a single advanced therapy. New trials suggest some combinations may improve remission...
Intestinal fibrosis is a serious complication of long-standing ulcerative colitis. Identifying NET-related biomarkers (IL1RN, MUC1, SERPINA1) could help researchers develop better diagnostic tools or treatments targeting...
The study tests whether adding MRI-based transmural assessment to a fecal-calprotectin–guided (CALM) strategy improves the ability to keep people with Crohn’s disease in corticosteroid-free clinical remission and may...
Lung involvement is an underrecognized extraintestinal complication in IBD and can reflect disease activity, altered gut–lung immune signaling, or medication toxicity — distinguishing the cause is important for...
Identifying an RNF213-marked Treg subset may help researchers understand immune mechanisms active in UC and could lead to new biomarker or therapeutic targets in the future.
Improved methods for profiling mucosa-associated microbiota from routine archival FFPE biopsies could expand research using stored pediatric gut samples, helping identify microbiome features linked to Crohn’s disease and...
Patients and clinicians often face primary non-response to anti‑TNF therapy. Identifying reproducible mucosal gene-expression patterns linked to non-response helps explain biological differences between responders and...
Spatial, high-plex mapping of immune cells in the colon helps reveal how immune cells and stromal cells are organized in IBD versus normal tissue. That information could help researchers identify new biomarkers or...
The study could improve prediction of who among first-degree relatives will develop Crohn's disease by combining blood biomarkers and lifestyle data, which may help earlier detection or targeted monitoring.
If confirmed, αvβ6 autoantibodies could help identify people at higher risk for ulcerative colitis and point to a new mechanism (blockade of epithelial TGF‑β activation) that contributes to mucosal inflammation.
RDW is part of a routine complete blood count and, if reliably associated with IBD activity, could offer a low-cost, widely available adjunctive biomarker for detecting disease and monitoring activity.
If validated, epithelial CXCL1 could become a tissue biomarker that helps track remission specifically in ulcerative colitis and serve as a functional readout for epithelial-directed therapies tested in patient-derived...
Early changes in stool tests (qFIT and fecal calprotectin) might help predict which biologic‑naive ulcerative colitis patients will relapse or need escalation to biologic/JAK therapy. If validated, such markers could...
Early, noninvasive stool tests (fecal calprotectin and FIT) might identify whether vedolizumab or infliximab is likely to work within weeks instead of months. That could let patients and clinicians make treatment...
The review suggests RDW, an inexpensive and widely available blood test parameter, is higher in IBD and correlates with disease activity—meaning it might help clinicians monitor disease alongside other tests.
The study identifies a candidate compound (NCTD) that reduced inflammation and tissue damage in a rat ulcerative colitis model and implicates specific inflammatory, epigenetic, metabolic, and antioxidant pathways —...
The study identifies specific induction exposure targets and biomarkers tied to higher chances of deep remission at 12 months in children on anti-TNF therapy, which could inform earlier dose optimization to improve...
This matters because identifying microbiome patterns linked to infliximab response could help predict which children with IBD are more likely to benefit from the drug and guide personalized treatment decisions in the...
Perianal fistulizing Crohn's disease is difficult to treat and many patients have failed anti-TNF therapy. Evidence that ustekinumab achieves high clinical fistula response and remission rates in a real-world multicenter...
The study suggests quality-of-life and patient-reported measures can reveal a subgroup of UC patients in clinical remission who nevertheless have higher relapse risk, which could help personalize monitoring and care.
Researchers are investigating RBM47 because it influences RNA processing and immune pathways that could modify inflammation and disease processes relevant to IBD. If borne out, RBM47 could become a biomarker or...
Sarcopenia is common in Crohn's disease and is linked to worse outcomes; a simple GNRI-based prediction tool could help identify at-risk patients without routine CT scanning.
Researchers report links between copper-driven cell death pathways and IBD biology; identifying cuproptosis-related biomarkers or drugs could open new diagnostic or therapeutic avenues for people with Crohn's disease or...
If you or your clinician are considering dietary therapy like the CDED for Crohn's disease, microbiome features at baseline may influence who achieves sustained remission. Understanding these links could help personalize...
Risk-prediction tools like CDPATH™ could help people with Crohn’s disease and their doctors identify higher or lower short-term risk of complications and guide treatment conversations. This study tests how the tool...
If validated, an early drop in fecal calprotectin could help identify patients on biologic therapy who are likely to achieve mucosal healing without waiting for invasive endoscopy, allowing earlier decisions about...
Digital self-management programs could help people with active IBD build skills to manage symptoms and quality of life between clinic visits. This trial tests whether such a program is feasible, acceptable, and practical...
Early intestinal ultrasound may predict one-year endoscopic remission in Crohn's disease, offering a noninvasive tool to guide treatment decisions and possibly reduce the need for some colonoscopies.
If fecal GP2 reliably reflects UC activity and microbial changes, it could become a noninvasive marker to track inflammation or to study disease mechanisms that differ between UC and CD.
Identifying patients at higher risk of hospitalization earlier could help clinicians target monitoring or treatment changes before clinical deterioration. Standard lab reference ranges may miss meaningful within-person...
FUT2 connects genetics, mucosal sugars, and the gut microbiome — pathways that could help explain why some people with IBD have different microbiomes or disease risk. If validated in trials, FUT2-targeted or...
This research links molecular subtypes of ulcerative colitis to infliximab (anti-TNF) response using an interpretable machine-learning method, which could help identify which patients are more or less likely to respond...
Oxidative stress may help explain some biological drivers of inflammation in Crohn’s disease and ulcerative colitis and could become a target for biomarkers or therapies in the future. Right now, the evidence is...
Non-invasive biomarkers that reflect mucosal inflammation and systemic disease activity could help reduce reliance on frequent endoscopy and guide monitoring for people with Crohn’s disease or ulcerative colitis.
Chronic pain affects many people with IBD even after inflammation is controlled, often limiting daily activities and worsening mental health. Understanding that pain can persist without active inflammation highlights the...
Blood markers that correlate with endoscopic healing could help track inflammation noninvasively and may reduce the frequency of endoscopy if validated. For people with IBD, better blood-based tools could make monitoring...
The study describes a new urine-based fluorescent biosensor that detected inflamed intestinal sites and tracked treatment response earlier and more sensitively than fecal calprotectin in a mouse model of IBD, which could...
This study suggests that subgrouping autoimmune diseases by a Traditional Chinese Medicine phenotype (Dampness ZHENG) corresponds to distinct T‑ and B‑cell receptor patterns.
PSC can progress to cirrhosis and cholangiocarcinoma; circulating multi-omic signatures that track severity and cancer-associated changes could help explain disease biology and lead to biomarkers for risk stratification...
This review suggests a new way to think about IBD relapse and disease persistence: persistent changes in innate immune cells (trained immunity) could maintain gut inflammation even when adaptive immune targets are...
Bowel urgency is a common symptom that may predict higher risk of treatment escalation, hospitalization, or surgery in UC even when bleeding and stool frequency look controlled. Better assessment of urgency in clinic...
The review highlights how microbial metabolites, epigenetic regulation, and mitochondrial metabolism interact to shape inflammation and barrier function in IBD. Understanding these links could help identify new...
Non-invasive urine biomarkers could make diagnosis and disease-activity monitoring easier and less invasive for people with IBD. Identifying metabolites linked to UC activity may help tailor monitoring without frequent...
